Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 09	CA/CAplus records now contain indexing from 1907 to the present
NEWS	4	AUG 05	New pricing for EUROPATFULL and PCTFULL effective August 1, 2003
NEWS	5	AUG 13	Field Availability (/FA) field enhanced in BEILSTEIN
NEWS	6	AUG 18	Data available for download as a PDF in RDISCLOSURE
NEWS	7	AUG 18	Simultaneous left and right truncation added to PASCAL
NEWS	8	AUG 18	FROSTI and KOSMET enhanced with Simultaneous Left and Righ Truncation
NEWS	9	AUG 18	Simultaneous left and right truncation added to ANABSTR
NEWS	10	SEP 22	DIPPR file reloaded
NEWS	11	SEP 25	INPADOC: Legal Status data to be reloaded
NEWS	12	SEP 29	DISSABS now available on STN
NEWS	13	OCT 10	PCTFULL: Two new display fields added
NEWS	14	OCT 21	BIOSIS file reloaded and enhanced
NEWS	15	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced

NEWS EXPRESS	OCTOBER 01 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:37:11 ON 04 NOV 2003

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

Patel <11/4/2003>

```
FILE 'REGISTRY' ENTERED AT 14:37:20 ON 04 NOV 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:     3 NOV 2003  HIGHEST RN 612478-18-9
DICTIONARY FILE UPDATES:    3 NOV 2003  HIGHEST RN 612478-18-9

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 10046526.3

L1      STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 14:37:48 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     20 TO ITERATE

100.0% PROCESSED      20 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          132 TO      668
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 14:37:54 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    326 TO ITERATE

100.0% PROCESSED     326 ITERATIONS                               1 ANSWERS
SEARCH TIME: 00.00.01

L3            1 SEA SSS FUL L1

=> file marpat
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             148.15     148.36

FILE 'MARPAT' ENTERED AT 14:38:09 ON 04 NOV 2003
```

FILE CONTENT: 1988-PRESENT (VOL 104 ISS 15-VOL 139 ISS18)(20031101ED)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 6627682 30 SEP 2003
DE 20300703 25 SEP 2003
EP 1350541 08 OCT 2003
JP 2003286251 10 OCT 2003
WO 2003082838 09 OCT 2003

Structure search limits have been raised. See HELP SLIMIT for the new, higher limits.

=> s l1 sss full
FULL SEARCH INITIATED 14:38:15 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED - 11133 TO ITERATE

37.5% PROCESSED 4174 ITERATIONS 0 ANSWERS

73.3% PROCESSED 8155 ITERATIONS 0 ANSWERS

95.3% PROCESSED 10611 ITERATIONS (1 INCOMPLETE) 1 ANSWERS

99.4% PROCESSED 11067 ITERATIONS (5 INCOMPLETE) 5 ANSWERS

100.0% PROCESSED 11133 ITERATIONS (5 INCOMPLETE) 5 ANSWERS
SEARCH TIME: 00.01.31

L4 5 SEA SSS FUL L1

=> d his

(FILE 'HOME' ENTERED AT 14:37:11 ON 04 NOV 2003)

FILE 'REGISTRY' ENTERED AT 14:37:20 ON 04 NOV 2003
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 1 S L1 SSS FULL

FILE 'MARPAT' ENTERED AT 14:38:09 ON 04 NOV 2003
L4 5 S L1 SSS FULL

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	105.35	253.71

FILE 'CAPLUS' ENTERED AT 14:40:03 ON 04 NOV 2003

FILE COVERS 1907 - 4 Nov 2003 VOL 139 ISS 19
FILE LAST UPDATED: 3 Nov 2003 (20031103/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d l5 fbib hitstr abs total
L5 NOT FOUND
The L-number entered has not been defined in this session, or it has been deleted. To see the L-numbers currently defined in this session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> s l3
L5 2 L3

=> s l4
L6 5 L4

=> s l5 and l6
L7 0 L5 AND L6

=> d l5 fbib hitstr abs total

L5 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:551181 CAPLUS
DN 139:117339
TI Preparation of substituted arylamine derivatives as antitumor agents
IN Elbaum, Daniel; Askew, Benny; Booker, Shon; Germain, Julie; Habgood, Gregory; Handley, Michael; Kim, Tae-Seong; Li, Aiwen; Nishimura, Nobuko; Patel, Vinod F.; Yuan, Chester Chenguang; Kim, Joseph L.
PA Amgen Inc., USA
SO U.S. Pat. Appl. Publ., 106 pp., Cont.-in-part of U.S. Ser. No. 46,526.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003134836	A1	20030717	US 2002-197960	20020717
				US 2001-261360PP	20010112
				US 2001-323686PP	20010919
				US 2002-46526 A2	20020110
	US 2002147198	A1	20021010	US 2002-46526	20020110
				US 2001-261360PP	20010112
				US 2001-323686PP	20010919

PATENT FAMILY INFORMATION:
FAN 2002:539663

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002055501	A2	20020718	WO 2002-US742	20020111
	WO 2002055501	A3	20021219		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-261360PP	20010112
				US 2001-323686PP	20010919
				US 2002-46526 A	20020110
	US 2002147198	A1	20021010	US 2002-46526	20020110
				US 2001-261360PP	20010112
				US 2001-323686PP	20010919

OS MARPAT 139:117339

IT **442846-35-7P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compd.; prepn. of substituted aminopyridines as antitumor agents)

RN 442846-35-7 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-[1-methyl-1-(1-methyl-4-piperidinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)



GI



I



II

AB The title compds. I [R2 = (un)substituted Ph, 9-10 membered bicyclic and 11-14 membered tricyclic (un)satd. heterocyclyl; R8 = halo, NH2, NO2, etc.], and their pharmaceutically acceptable derivs., are prepd. and disclosed as agents effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. E.g., a multi-step synthesis of II, starting from 1-dimethylamino-2-propyne and 3-bromo-5-trifluoromethylaniline, was given. Selected compds. of the invention, e.g., II, inhibited VEGF-stimulated cell proliferation at a level below 50 nM. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable derivs. thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like.

L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:539663 CAPLUS
DN 137:109210
TI Preparation of substituted arylamine derivatives and methods of use as antitumor agents
IN Chen, Guoqing; Booker, Shon; Cai, Guolin; Croghan, Michael; Dipietro, Lucian; Dominguez, Celia; Elbaum, Daniel; Germain, Julie; Huang, Qi; Kim, Joseph L.; Kim, Tae-Seong; Patel, Vinod F.; Smith, Leon M.; Tasker, Andrew; Xi, Ning; Xu, Shimin; Yuan, Chester Chenguang
PA Amgen Inc., USA
SO PCT Int. Appl., 253 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002055501	A2	20020718	WO 2002-US742	20020111
	WO 2002055501	A3	20021219		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,

CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2001-261360PP 20010112
US 2001-323686PP 20010919
US 2002-46526 A 20020110

US 2002147198 A1 20021010
US 2002-46526 20020110
US 2001-261360PP 20010112
US 2001-323686PP 20010919

PATENT FAMILY INFORMATION:

FAN 2003:551181

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003134836	A1	20030717	US 2002-197960	20020717
				US 2001-261360PP	20010112
				US 2001-323686PP	20010919
				US 2002-46526 A2	20020110
	US 2002147198	A1	20021010	US 2002-46526	20020110
				US 2001-261360PP	20010112
				US 2001-323686PP	20010919

OS MARPAT 137:109210

IT **442846-35-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compd.; prepn. of substituted aminopyridines as antitumor agents)

RN 442846-35-7 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-[1-methyl-1-(1-methyl-4-piperidinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)



GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [B1 and B2 independently equal C or N, wherein B1B2 form part of 5-6 membered heteroaryl ring A; R1 = one or more substituents

selected from H, halo, oxo, (un)substituted cycloalkyl, phenylalkyl, etc.; R2 = (un)substituted cycloalkyl, cycloalkenyl, 6-10 membered aryl or 5-6 membered heterocyclyl, etc.; R3 = (un)substituted aryl; R4 = H, alkyl, (un)substituted Ph or aralkyl; X1 = bond, alkylenyl, alkenylenyl and alkynylenyl, where one of the CH2 groups may be substituted with O or NH, wherein X1 is optionally substituted with OH; X2 = (un)substituted N contg. linker, e.g., -NHCH2-], and there pharmaceutically acceptable derivs., are prepd. and disclosed as agents effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. Thus, II was prepd. via arylation of 1-dimethylamino-2-propyne with 3-bromo-5-trifluoromethylaniline, hydrogenation, amidation with 2-chloropyridine-3-carbonyl chloride and chloro-substitution with 4-fluorobenzylamine. Selected compds. of the invention, e.g., II, inhibited VEGF-stimulated cell proliferation at a level below 50 nM. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable derivs. thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like.

=> d his

(FILE 'HOME' ENTERED AT 14:37:11 ON 04 NOV 2003)

FILE 'REGISTRY' ENTERED AT 14:37:20 ON 04 NOV 2003
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 1 S L1 SSS FULL

FILE 'MARPAT' ENTERED AT 14:38:09 ON 04 NOV 2003
L4 5 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 14:40:03 ON 04 NOV 2003
L5 2 S L3
L6 5 S L4
L7 0 S L5 AND L6

=> d l4 fbib hitstr abs total
YOU HAVE REQUESTED DATA FROM FILE 'MARPAT' - CONTINUE? (Y)/N:n

=> d l6 fbib hitstr abs total

L6 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:290791 CAPLUS
DN **136:309922**
TI Preparation of benzoxazolyl piperidines and analogs as rotamase enzyme inhibitors
IN Kemp, Mark Ian; Palmer, Michael John; Sanner, Mark Allen; Wythes, Martin James
PA Pfizer Inc, USA
SO U.S., 43 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	US 6372736	B1	20020416	US 1999-358107	19990721
	US 6562964	B1	20030513	US 2002-56901	20020123
				GB 1998-15880 A	19980721
				US 1999-358107 A3	19990721

PATENT FAMILY INFORMATION:

FAN 2000:84802

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000005232	A1	20000203	WO 1999-IB1211	19990628
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				GB 1998-15880 A	19980721
	CA 2338214	AA	20000203	CA 1999-2338214	19990628
				GB 1998-15880 A	19980721
				WO 1999-IB1211 W	19990628
	AU 9942858	A1	20000214	AU 1999-42858	19990628
				GB 1998-15880 A	19980721
				WO 1999-IB1211 W	19990628
	BR 9912330	A	20010417	BR 1999-12330	19990628
				GB 1998-15880 A	19980721
				WO 1999-IB1211 W	19990628
	EP 1100797	A1	20010523	EP 1999-963123	19990628
	EP 1100797	B1	20030226		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
				GB 1998-15880 A	19980721
				WO 1999-IB1211 W	19990628
	EE 200100044	A	20020617	EE 2001-44	19990628
				GB 1998-15880 A	19980721
				WO 1999-IB1211 W	19990628
	JP 2002521382	T2	20020716	JP 2000-561188	19990628
				GB 1998-15880 A	19980721
				WO 1999-IB1211 W	19990628
	NZ 508838	A	20021220	NZ 1999-508838	19990628
				GB 1998-15880 A	19980721
				WO 1999-IB1211 W	19990628
	AT 233261	E	20030315	AT 1999-963123	19990628
				GB 1998-15880 A	19980721
				WO 1999-IB1211 W	19990628
	ES 2191484	T3	20030901	ES 1999-963123	19990628
				GB 1998-15880 A	19980721
	NO 2001000322	A	20010315	NO 2001-322	20010119
				GB 1998-15880 A	19980721
				WO 1999-IB1211 W	19990628
	HR 2001000052	A1	20011231	HR 2001-52	20010119
				GB 1998-15880 A	19980721
				WO 1999-IB1211 W	19990628
	BG 105254	A	20011031	BG 2001-105254	20010214
				GB 1998-15880 A	19980721
				WO 1999-IB1211 W	19990628

OS MARPAT 136:309922

GI



I



II

AB Title compds. [I; A = (un)substituted unbranched C3-C5 alkylene; X and Y = independently O, S, NH, or N-alkyl; R = (un)substituted, C-linked, 4- to 6-membered, non-arom., heterocyclic ring contg. 1 N; R1-R4 = independently H, halo, (cyclo)alkyl, haloalkyl, (cyclo)alkoxy, CONR5R6, cycloalkylalkylene, cycloalkylalkoxy, or CO2R7; R5 and R6 = independently H, alkyl, or taken together = unbranched alkylene; R7 = alkyl] were prepd. as rotamase enzyme inhibitors, particularly FKBP-12 and FKBP-52 inhibitors. Thus, (2S)-1-(1,3-benzoxazol-2-yl)-2-piperidinecarboxylic acid (prepn. given) was amidated with (3S)-1-benzylpyrrolidine-3-ylamine in the presence of 1-hydroxybenzotriazole hydrate and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide.HCl in CH2Cl2 to yield II. Twenty-one compds. of the invention demonstrated inhibitory activity against human recombinant FKBP-12 in a coupled colorimetric PPIase in vitro assay with IC50 values below 1200 nM, and II inhibited the rotamase enzyme FKBP-52 in a similar assay with IC50 = 2790 nM. As neurotrophic agents, the invention compds. promote neuronal regeneration and outgrowth and are useful for the treatment of neurodegenerative diseases or other disorders involving nerve damage.

RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:277965 CAPLUS
DN **132:308336**
TI Novel imidazoles with anti-inflammatory activity and their preparation and use
IN Almansa, Carmen; Gonzalez, Concepcion; Torres, M<<fml Carmen
PA J. Uriach & Cia, S.A., Spain
SO PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DT Patent
LA Spanish
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000023426	A1	20000427	WO 1999-ES327	19991015

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,

MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

			ES 1998-2222	A 19981016
CA 2346847	AA	20000427	CA 1999-2346847	19991015
			ES 1998-2222	A 19981016
			WO 1999-ES327	W 19991015
AU 9962048	A1	20000508	AU 1999-62048	19991015
			ES 1998-2222	A 19981016
			WO 1999-ES327	W 19991015
EP 1122243	A1	20010808	EP 1999-949025	19991015
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
			ES 1998-2222	A 19981016
			WO 1999-ES327	W 19991015
BR 9914571	A	20011106	BR 1999-14571	19991015
			ES 1998-2222	A 19981016
			WO 1999-ES327	W 19991015
JP 2002527508	T2	20020827	JP 2000-577154	19991015
			ES 1998-2222	A 19981016
			WO 1999-ES327	W 19991015
NO 2001001790	A	20010614	NO 2001-1790	20010409
			ES 1998-2222	A 19981016
			WO 1999-ES327	W 19991015

OS MARPAT 132:308336

GI



I II

AB Title compds. I are disclosed [wherein one of X or Y = N; other = C; R1 = H, Me, halo, cyano, NO2, CHO, COCH3 or COOR4; R2 = (un)substituted aryl or heteroaryl; R3 = C1-8 alkyl, C1-8 haloalkyl, or NR4R6; R4 = H, C1-8 alkyl, or (un)substituted aryl(alkyl); R6 = H, C1-8 alkyl, arylalkyl, COR8, or CO2R8; R8 = C1-8 alkyl or C1-8 haloalkyl; aryl = Ph or naphthyl; heteroaryl = pyridyl, pyrazinyl, pyrimidinyl, or pyridazinyl, optionally fused to a benzene ring]. The compds. are useful as selective inhibitors of cyclooxygenase-2 (COX-2), and particularly as antiinflammatories. Claimed uses include treatment of inflammation, pain, fever,

prostanoid-induced smooth muscle contraction, dysmenorrhea, premature labor, asthma, bronchitis, cancer (esp. gastrointestinal or colon), cerebral infarct, epilepsy, or neurodegenerative diseases such as Alzheimer's disease or dementia. For instance, 4-(MeSO2)C6H4NH2 was condensed with 4-FC6H4CHO under Dean-Stark conditions, and the resulting imine was cyclized with tosylmethyl isocyanide (75%), followed by imidazole ring chlorination with N-chlorosuccinimide (80%), to give the invention compd. II. This compd. gave 89% inhibition of COX-2 at 1 .mu.M in vitro, but only 37.8% inhibition of COX-1 at 10 .mu.M.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:84802 CAPLUS
DN **132:137377**
TI Preparation of benzoxazolyl piperidines and analogs as rotamase enzyme inhibitors
IN Kemp, Mark Ian; Palmer, Michael John; Sanner, Mark Allen; Wythes, Martin James
PA Pfizer Limited, UK; Pfizer Inc.
SO PCT Int. Appl., 131 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000005232	A1	20000203	WO 1999-IB1211	19990628
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
			GB 1998-15880 A	19980721
CA 2338214	AA	20000203	CA 1999-2338214	19990628
			GB 1998-15880 A	19980721
			WO 1999-IB1211 W	19990628
AU 9942858	A1	20000214	AU 1999-42858	19990628
			GB 1998-15880 A	19980721
			WO 1999-IB1211 W	19990628
BR 9912330	A	20010417	BR 1999-12330	19990628
			GB 1998-15880 A	19980721
			WO 1999-IB1211 W	19990628
EP 1100797	A1	20010523	EP 1999-963123	19990628
EP 1100797	B1	20030226		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
			GB 1998-15880 A	19980721
			WO 1999-IB1211 W	19990628
EE 200100044	A	20020617	EE 2001-44	19990628
			GB 1998-15880 A	19980721
			WO 1999-IB1211 W	19990628
JP 2002521382	T2	20020716	JP 2000-561188	19990628
			GB 1998-15880 A	19980721

			WO 1999-IB1211 W 19990628
NZ 508838	A	20021220	NZ 1999-508838 19990628
			GB 1998-15880 A 19980721
			WO 1999-IB1211 W 19990628
AT 233261	E	20030315	AT 1999-963123 19990628
			GB 1998-15880 A 19980721
			WO 1999-IB1211 W 19990628
ES 2191484	T3	20030901	ES 1999-963123 19990628
			GB 1998-15880 A 19980721
NO 2001000322	A	20010315	NO 2001-322 20010119
			GB 1998-15880 A 19980721
			WO 1999-IB1211 W 19990628
HR 2001000052	A1	20011231	HR 2001-52 20010119
			GB 1998-15880 A 19980721
			WO 1999-IB1211 W 19990628
BG 105254	A	20011031	BG 2001-105254 20010214
			GB 1998-15880 A 19980721
			WO 1999-IB1211 W 19990628

PATENT FAMILY INFORMATION:

FAN 2002:290791

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6372736	B1	20020416	US 1999-358107	19990721
	US 6562964	B1	20030513	US 2002-56901	20020123
				GB 1998-15880 A	19980721
				US 1999-358107 A3	19990721

OS MARPAT 132:137377

GI



I



II

AB Title compds. (I) [wherein A = (un)substituted unbranched C3-C5 alkylene; X and Y = independently O, S, NH, or N-alkyl; R = (un)substituted, C-linked, 4- to 6-membered, non-arom., heterocyclic ring contg. 1 N; R1-R4 = independently H, halo, (cyclo)alkyl, haloalkyl, (cyclo)alkoxy, CONR5R6, cycloalkylalkylene, cycloalkylalkoxy, or CO2R7; R5 and R6 = independently H, alkyl, or taken together = unbranched alkylene; R7 = alkyl] were prepd. as rotamase enzyme inhibitors, particularly FKBP-12 and FKBP-52 inhibitors. Thus, (2S)-1-(1,3-benzoxazol-2-yl)-2-piperidinecarboxylic acid (prepn. given) was amidated with (3S)-1-benzylpyrrolidine-3-ylamine in the presence of 1-hydroxybenzotriazole hydrate and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide.HCl in CH2Cl2 to yield II. Twenty-one compds. of the invention demonstrated inhibitory activity

against human recombinant FKBP-12 in a coupled colorimetric PPIase in vitro assay with IC50 values below 1200 nM, and II inhibited the rotamase enzyme FKBP-52 in a similar assay with IC50 = 2790 nM. As neurotrophic agents, the invention compds. promote neuronal regeneration and outgrowth and are useful for the treatment of neurodegenerative diseases or other disorders involving nerve damage.

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:719132 CAPLUS
DN **129:343719**
TI Preparation of hemoregulatory peptides for stimulating the myelopoietic system
IN Bhatnagar, Pradip Kumar; Heerding, Dirk; Fischer, Peter Martin
PA Smithkline Beecham Corporation, USA; Nycomed Pharma As
SO U.S., 20 pp., Cont.-in-part of U.S. Ser. No. 66,952, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5830867	A	19981103	US 1996-553562	19960130
				US 1993-66952 B2	19930524
				US 1993-150524 B2	19931109
				WO 1994-US5859 W	19940524
	WO 9427627	A1	19941208	WO 1994-US5859	19940524
	W: AU, BB, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, UA, US, US, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
				US 1993-66952 A	19930524
				US 1993-150524 A	19931109
	ZA 9403737	A	19950202	ZA 1994-3737	19940527
				US 1993-150524	19931109

PATENT FAMILY INFORMATION:
FAN 1995:750514

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9427627	A1	19941208	WO 1994-US5859	19940524
	W: AU, BB, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, UA, US, US, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
				US 1993-66952 A	19930524
				US 1993-150524 A	19931109
	AU 9470449	A1	19941220	AU 1994-70449	19940524
				US 1993-66952 A	19930524
				US 1993-150524 A	19931109
				WO 1994-US5859 W	19940524
	EP 701446	A1	19960320	EP 1994-919232	19940524
	R: BE, CH, DE, FR, GB, IT, LI, NL				
				US 1993-66952 A	19930524
				US 1993-150524 A	19931109
				WO 1994-US5859 W	19940524
	JP 09504266	T2	19970428	JP 1995-500916	19940524
				US 1993-66952 A	19930524

				US 1993-150524 A	19931109
				WO 1994-US5859 W	19940524
	ZA 9403737	A	19950202	ZA 1994-3737	19940527
				US 1993-150524	19931109
	US 5830867	A	19981103	US 1996-553562	19960130
				US 1993-66952	B219930524
				US 1993-150524	B219931109
				WO 1994-US5859 W	19940524

OS MARPAT 129:343719

AB Peptides A1-B1-X1-(CH2)m-(CONR1)r-(CH2)s-Y1-(CH2)s-(NR1CO)r-(CH2)n-X1-B1-A1 [A1 = certain amino acids or aza heterocyclic acids; B1 = certain amino acids, 2-amino-3-hydroxythiopropanoic acid, 2-amino-1-hydroxypropyl, or 2-amino-1-hydroxypent-3-enyl; X1 = O, S, NR1, CR2R3; Y1 = O, S, NR1, CR2R3, imidazolyl, triazolyl, Ph, etc.; R1, R2, R3 = H, alkyl, imidazolyl, benzyl, etc.; m, n = 0-5; r = 0-2; s = 0, 1] were prepd. for stimulating the myelopoietic system. Thus, N,N'-bis(picolinoyl-seryl-.beta.-alanyl)-1,4-diaminobenzene (Boc = tert-butoxycarbonyl) was prepd. from 1,4-phenylenediamine dihydrochloride, Boc-.beta.-Ala-OH, Boc-Ser(Bzl)-OH, and picolinic acid.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1993:552116 CAPLUS

DN **119:152116**

TI Use of renin inhibitors for the treatment of glaucoma

IN Tanaka, Yoko; Kagayama, Akira; Hata, Takehisa

PA Fujisawa Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 25 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9312796	A1	19930708	WO 1992-JP1656	19921218
	W: AU, CA, HU, JP, KR, RU, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				GB 1991-27041	19911220
	ZA 9209738	A	19930617	ZA 1992-9738	19921215
				GB 1991-27041	19911220
	AU 9331712	A1	19930728	AU 1993-31712	19921218
	AU 661748	B2	19950803		
				GB 1991-27041	19911220
				WO 1992-JP1656	19921218
	EP 617622	A1	19941005	EP 1993-900396	19921218
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
				GB 1991-27041	19911220
				WO 1992-JP1656	19921218
	JP 07506807	T2	19950727	JP 1992-511545	19921218
				GB 1991-27041	19911220
				WO 1992-JP1656	19921218
	CN 1088934	A	19940706	CN 1993-101190	19930102
				GB 1991-27041	19911220

OS MARPAT 119:152116

GI



I

AB The renin-inhibiting histidine derivs. I [R1 = (un)substituted alkyl or amino; R2, R3 = H, alkyl; NR1R2 = heterocyclyl; R4 = alkyl] or I salts are drugs for the treatment of glaucoma. Eye application of 0.2% 2(S)-[N.alpha.-[2(S)-[N-methyl-N-[2-[N-(morpholinocarbonyl)-N-methylamino]ethyl]aminocarbonyloxy]-3-phenylpropionyl]-N.alpha.-methyl-L-histidyl]amino-1-cyclohexyl-3(S)-hydroxy-6-methylheptane-HCl lower intraocular pressure in the rabbit.

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	53.00	306.71

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.56	-4.56

STN INTERNATIONAL LOGOFF AT 14:42:44 ON 04 NOV 2003

Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 09	CA/CAplus records now contain indexing from 1907 to the present
NEWS	4	AUG 05	New pricing for EUROPATFULL and PCTFULL effective August 1, 2003
NEWS	5	AUG 13	Field Availability (/FA) field enhanced in BEILSTEIN
NEWS	6	AUG 18	Data available for download as a PDF in RDISCLOSURE
NEWS	7	AUG 18	Simultaneous left and right truncation added to PASCAL
NEWS	8	AUG 18	FROSTI and KOSMET enhanced with Simultaneous Left and Righ Truncation
NEWS	9	AUG 18	Simultaneous left and right truncation added to ANABSTR
NEWS	10	SEP 22	DIPPR file reloaded
NEWS	11	SEP 25	INPADOC: Legal Status data to be reloaded
NEWS	12	SEP 29	DISSABS now available on STN
NEWS	13	OCT 10	PCTFULL: Two new display fields added
NEWS	14	OCT 21	BIOSIS file reloaded and enhanced
NEWS	15	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced

NEWS EXPRESS	OCTOBER 01 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:58:07 ON 04 NOV 2003

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

Patel <11/4/2003>

FILE 'REGISTRY' ENTERED AT 14:58:22 ON 04 NOV 2003

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 NOV 2003 HIGHEST RN 612478-18-9
DICTIONARY FILE UPDATES: 3 NOV 2003 HIGHEST RN 612478-18-9

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 10046526.7

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 S,SO2
G2 Cb,Cy,Hy

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss full
FULL SEARCH INITIATED 14:58:46 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    779 TO ITERATE

100.0% PROCESSED     779 ITERATIONS                              2 ANSWERS
SEARCH TIME: 00.00.01

L2            2 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   148.15     148.36

FILE 'CAPLUS' ENTERED AT 14:58:54 ON 04 NOV 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 4 Nov 2003  VOL 139 ISS 19
FILE LAST UPDATED: 3 Nov 2003  (20031103/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> s l2
L3            2 L2

=> d l3 fbib hitstr abs total

L3   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   2003:551181  CAPLUS
DN   139:117339
TI   Preparation of substituted arylamine derivatives as antitumor agents
IN   Elbaum, Daniel; Askew, Benny; Booker, Shon; Germain, Julie; Habgood,
     Gregory; Handley, Michael; Kim, Tae-Seong; Li, Aiwen; Nishimura, Nobuko;
     Patel, Vinod F.; Yuan, Chester Chenguang; Kim, Joseph L.
PA   Amgen Inc., USA
SO   U.S. Pat. Appl. Publ., 106 pp., Cont.-in-part of U.S. Ser. No. 46,526.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 2
     PATENT NO.       KIND  DATE          APPLICATION NO.  DATE
```

PI	US 2003134836	A1	20030717	US 2002-197960	20020717
				US 2001-261360PP	20010112
				US 2001-323686PP	20010919
				US 2002-46526 A2	20020110
	US 2002147198	A1	20021010	US 2002-46526	20020110
				US 2001-261360PP	20010112
				US 2001-323686PP	20010919

PATENT FAMILY INFORMATION:

FAN 2002:539663

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002055501	A2	20020718	WO 2002-US742	20020111
	WO 2002055501	A3	20021219		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

				US 2001-261360PP	20010112
				US 2001-323686PP	20010919
				US 2002-46526 A	20020110
	US 2002147198	A1	20021010	US 2002-46526	20020110
				US 2001-261360PP	20010112
				US 2001-323686PP	20010919

OS MARPAT 139:117339

IT **561297-64-1P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of substituted aminopyridines as antitumor agents)

RN 561297-64-1 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-[1-methyl-1-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]phenyl]- (9CI) (CA INDEX NAME)



IT **442846-35-7P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compd.; prepn. of substituted aminopyridines as antitumor agents)

RN 442846-35-7 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-[1-methyl-1-(1-methyl-4-piperidinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)



GI



I II

AB The title compds. I [R2 = (un)substituted Ph, 9-10 membered bicyclic and 11-14 membered tricyclic (un)satd. heterocyclyl; R8 = halo, NH2, NO2, etc.], and their pharmaceutically acceptable derivs., are prepd. and disclosed as agents effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. E.g., a multi-step synthesis of II, starting from 1-dimethylamino-2-propyne and 3-bromo-5-trifluoromethylaniline, was given. Selected compds. of the invention,

e.g., II, inhibited VEGF-stimulated cell proliferation at a level below 50 nM. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable derivs. thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like.

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:539663 CAPLUS
DN 137:109210
TI Preparation of substituted arylamine derivatives and methods of use as antitumor agents
IN Chen, Guoqing; Booker, Shon; Cai, Guolin; Croghan, Michael; Dipietro, Lucian; Dominguez, Celia; Elbaum, Daniel; Germain, Julie; Huang, Qi; Kim, Joseph L.; Kim, Tae-Seong; Patel, Vinod F.; Smith, Leon M.; Tasker, Andrew; Xi, Ning; Xu, Shimin; Yuan, Chester Chenguang
PA Amgen Inc., USA
SO PCT Int. Appl., 253 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002055501	A2	20020718	WO 2002-US742	20020111
	WO 2002055501	A3	20021219		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-261360PP	20010112
				US 2001-323686PP	20010919
				US 2002-46526 A	20020110
	US 2002147198	A1	20021010	US 2002-46526	20020110
				US 2001-261360PP	20010112
				US 2001-323686PP	20010919

PATENT FAMILY INFORMATION:
FAN 2003:551181

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003134836	A1	20030717	US 2002-197960	20020717
				US 2001-261360PP	20010112
				US 2001-323686PP	20010919
				US 2002-46526 A220020110	
	US 2002147198	A1	20021010	US 2002-46526	20020110
				US 2001-261360PP	20010112
				US 2001-323686PP	20010919

OS MARPAT 137:109210
IT **442846-35-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compd.; prepn. of substituted aminopyridines as antitumor agents)

RN 442846-35-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-[1-methyl-1-(1-methyl-4-piperidinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)



GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [B1 and B2 independently equal C or N, wherein B1B2 form part of 5-6 membered heteroaryl ring A; R1 = one or more substituents selected from H, halo, oxo, (un)substituted cycloalkyl, phenylalkyl, etc.; R2 = (un)substituted cycloalkyl, cycloalkenyl, 6-10 membered aryl or 5-6 membered heterocyclyl, etc.; R3 = (un)substituted aryl; R4 = H, alkyl, (un)substituted Ph or aralkyl; X1 = bond, alkylenyl, alkenylenyl and alkynylenyl, where one of the CH2 groups may be substituted with O or NH, wherein X1 is optionally substituted with OH; X2 = (un)substituted N contg. linker, e.g., -NHCH2-], and there pharmaceutically acceptable derivs., are prepd. and disclosed as agents effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. Thus, II was prepd. via arylation of 1-dimethylamino-2-propyne with 3-bromo-5-trifluoromethylaniline, hydrogenation, amidation with 2-chloropyridine-3-carbonyl chloride and chloro-substitution with 4-fluorobenzylamine. Selected compds. of the invention, e.g., II, inhibited VEGF-stimulated cell proliferation at a level below 50 nM. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable derivs. thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like.

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	21.56	169.92

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL

	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.30	-1.30

STN INTERNATIONAL LOGOFF AT 14:59:18 ON 04 NOV 2003

Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'HOME' AT 13:18:23 ON 30 JUN 2003
FILE 'HOME' ENTERED AT 13:18:23 ON 30 JUN 2003

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.63	0.63

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.63	0.63

FILE 'REGISTRY' ENTERED AT 13:18:37 ON 30 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 JUN 2003 HIGHEST RN 539790-82-4
DICTIONARY FILE UPDATES: 29 JUN 2003 HIGHEST RN 539790-82-4

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 10046526.1

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 13:19:04 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      7 TO ITERATE

100.0% PROCESSED       7 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            7 TO      298
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 13:19:12 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     85 TO ITERATE

100.0% PROCESSED      85 ITERATIONS                                1 ANSWERS
SEARCH TIME: 00.00.01

L3            1 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
```

	ENTRY	SESSION
FULL ESTIMATED COST	148.15	148.78

FILE 'CAPLUS' ENTERED AT 13:19:17 ON 30 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 30 Jun 2003 VOL 139 ISS 1
FILE LAST UPDATED: 29 Jun 2003 (20030629/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l3
L4            1 L3

=> d l4 fbib hitstr abs total

L4   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2003 ACS
AN   2002:539663  CAPLUS
DN   137:109210
TI   Preparation of substituted arylamine derivatives and methods of use as
     antitumor agents
IN   Chen, Guoqing; Booker, Shon; Cai, Guolin; Croghan, Michael; Dipietro,
     Lucian; Dominguez, Celia; Elbaum, Daniel; Germain, Julie; Huang, Qi; Kim,
     Joseph L.; Kim, Tae-Seong; Patel, Vinod F.; Smith, Leon M.; Tasker,
     Andrew; Xi, Ning; Xu, Shimin; Yuan, Chester Chenguang
PA   Amgen Inc., USA
SO   PCT Int. Appl., 253 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.         KIND  DATE          APPLICATION NO.  DATE
     ---------------    ----  --------      ---------------  --------
PI   WO 2002055501      A2    20020718      WO 2002-US742    20020111
     WO 2002055501      A3    20021219
          W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
              CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
              GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
              LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
              PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
              UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
          RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
              CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
```

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2001-261360PP 20010112
US 2001-323686PP 20010919
US 2002-46526 A 20020110

US 2002147198 A1 20021010
US 2002-46526 20020110
US 2001-261360PP 20010112
US 2001-323686PP 20010919

OS MARPAT 137:109210

IT **442846-35-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compd.; prepn. of substituted aminopyridines as antitumor agents)

RN 442846-35-7 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-[1-methyl-1-(1-methyl-4-piperidinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)



GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [B1 and B2 independently equal C or N, wherein B1B2 form part of 5-6 membered heteroaryl ring A; R1 = one or more substituents selected from H, halo, oxo, (un)substituted cycloalkyl, phenylalkyl, etc.; R2 = (un)substituted cycloalkyl, cycloalkenyl, 6-10 membered aryl or 5-6 membered heterocyclyl, etc.; R3 = (un)substituted aryl; R4 = H, alkyl, (un)substituted Ph or aralkyl; X1 = bond, alkylenyl, alkenylenyl and alkynylenyl, where one of the CH2 groups may be substituted with O or NH, wherein X1 is optionally substituted with OH; X2 = (un)substituted N contg. linker, e.g., -NHCH2-], and there pharmaceutically acceptable derivs., are prepd. and disclosed as agents effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. Thus, II was prepd. via arylation of 1-dimethylamino-2-propyne with 3-bromo-5-trifluoromethylaniline, hydrogenation, amidation with 2-chloropyridine-3-carbonyl chloride and chloro-substitution with

4-phenoxyaniline. Selected compds. of the invention, e.g., II, inhibited VEGF-stimulated cell proliferation at a level below 50 nM. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable derivs. thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like.

=> d cost

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
CONNECT CHARGES	0.34	1.13
NETWORK CHARGES	0.06	0.30
SEARCH CHARGES	0.00	147.75
DISPLAY CHARGES	4.32	4.32
	4.72	153.50
CAPLUS FEE (5%)	0.23	0.23
FULL ESTIMATED COST	4.95	153.73

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.65	-0.65

IN FILE 'CAPLUS' AT 13:19:53 ON 30 JUN 2003

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.79	154.57

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.65	-0.65

STN INTERNATIONAL LOGOFF AT 13:21:02 ON 30 JUN 2003

Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	Jun 03	New e-mail delivery for search results now available
NEWS 4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 7	Sep 03	JAPIO has been reloaded and enhanced
NEWS 8	Sep 16	Experimental properties added to the REGISTRY file
NEWS 9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 11	Oct 24	BEILSTEIN adds new search fields
NEWS 12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 13	Nov 18	DKILIT has been renamed APOLLIT
NEWS 14	Nov 25	More calculated properties added to REGISTRY
NEWS 15	Dec 04	CSA files on STN
NEWS 16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 17	Dec 17	TOXCENTER enhanced with additional content
NEWS 18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS 20	Feb 13	CANCERLIT is no longer being updated
NEWS 21	Feb 24	METADEX enhancements
NEWS 22	Feb 24	PCTGEN now available on STN
NEWS 23	Feb 24	TEMA now available on STN
NEWS 24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS 25	Feb 26	PCTFULL now contains images
NEWS 26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 27	Mar 20	EVENTLINE will be removed from STN
NEWS 28	Mar 24	PATDPAFULL now available on STN
NEWS 29	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS 30	Apr 11	Display formats in DGENE enhanced
NEWS 31	Apr 14	MEDLINE Reload
NEWS 32	Apr 17	Polymer searching in REGISTRY enhanced
NEWS 33	Jun 13	Indexing from 1947 to 1956 added to records in CA/CAPLUS
NEWS 34	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS 35	Apr 28	RDISCLOSURE now available on STN
NEWS 36	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS 37	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS 38	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 39	May 16	CHEMREACT will be removed from STN
NEWS 40	May 19	Simultaneous left and right truncation added to WSCA

Patel <11/4/2003>

```
 NEWS 41  May 19  RAPRA enhanced with new search field, simultaneous left and
                  right truncation
 NEWS 42  Jun 06  Simultaneous left and right truncation added to CBNB
 NEWS 43  Jun 06  PASCAL enhanced with additional data
 NEWS 44  Jun 20  2003 edition of the FSTA Thesaurus is now available
 NEWS 45  Jun 25  HSDB has been reloaded

 NEWS EXPRESS  April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:25:55 ON 30 JUN 2003

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'REGISTRY' ENTERED AT 13:26:04 ON 30 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   29 JUN 2003  HIGHEST RN 539790-82-4
DICTIONARY FILE UPDATES:  29 JUN 2003  HIGHEST RN 539790-82-4

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
```

Uploading 10046526.2

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 Cb,Cy,Hy,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 13:26:26 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2066 TO ITERATE

48.4% PROCESSED 1000 ITERATIONS 10 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 38594 TO 44046
PROJECTED ANSWERS: 141 TO 685

L2 10 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 13:26:33 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 40731 TO ITERATE

100.0% PROCESSED 40731 ITERATIONS 255 ANSWERS
SEARCH TIME: 00.00.02

L3 255 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 148.15 148.36

FILE 'CAPLUS' ENTERED AT 13:26:41 ON 30 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 30 Jun 2003 VOL 139 ISS 1
FILE LAST UPDATED: 29 Jun 2003 (20030629/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 20 L3

=> d l4 fbib hitstr abs total

L4 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2003 ACS
AN 2003:319701 CAPLUS
DN 138:337840
TI Preparation of 5'-acylamino-1,1'-biphenyl-4-carboxamides as p38 kinase inhibitors
IN Angell, Richard Martyn; Aston, Nicola Mary; Bamborough, Paul; Bamford, Mark James; Cockerill, George Stuart; Flack, Stephen Sean; Laine, Dramane Ibrahim; Merrick, Suzanne Joy; Smith, Kathryn Jane; Walker, Ann Louise
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003032971	A1	20030424	WO 2002-EP11576	20021016

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

GB 2001-24939 A 20011017

OS MARPAT 138:337840

IT **515812-31-4P 515812-32-5P 515812-34-7P 515812-35-8P 515812-44-9P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 5'-acylamino-1,1'-biphenyl-4-carboxamides as p38 kinase inhibitors)

RN 515812-31-4 CAPLUS

CN 4-Pyridinecarboxamide, 2-[(cyclopropylmethyl)amino]-N-[4'-[[(cyclopropylmethyl)amino]carbonyl]-6-methyl[1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)



RN 515812-32-5 CAPLUS

CN 4-Pyridinecarboxamide, N-[4'-[[(cyclopropylmethyl)amino]carbonyl]-6-methyl[1,1'-biphenyl]-3-yl]-2-[(2-methylpropyl)amino]- (9CI) (CA INDEX NAME)



RN 515812-34-7 CAPLUS

CN 4-Pyridinecarboxamide, 2-(cyclohexylamino)-N-[4'-[[(cyclopropylmethyl)amino]carbonyl]-6-methyl[1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)



RN 515812-35-8 CAPLUS
CN 4-Pyridinecarboxamide, 2-(cyclopropylamino)-N-[4'-[[(cyclopropylmethyl)amino]carbonyl]-6-methyl[1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)



RN 515812-44-9 CAPLUS
CN 4-Pyridinecarboxamide, 2-(cyclobutylamino)-N-[4'-[[(cyclopropylmethyl)amino]carbonyl]-6-methyl[1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)



GI



I



II

AB The title compds. [I; when m = 0-4, R1 = alkyl, cycloalkyl, alkenyl, etc.; when m = 2-4, R1 addnl. = alkoxy, OH, etc.; R2 = H, alkyl, (CH2)ncycloalkyl; R3 = NHCOR6 (wherein R6 = H, alkyl, alkoxy, etc.); U = Me, halo; W = Me, Cl; X, Y = H, Me, halo; m = 0-4; n = 0-1; s = 0-2], useful as pharmaceuticals, particularly as p38 kinase inhibitors, were prepd. E.g., a 6-step synthesis of the nicotinamide II, starting with 3-bromo-4-methylaniline, was given.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2003 ACS
AN 2003:261670 CAPLUS
DN 138:287666
TI Preparation of heteroaryllactams as Factor Xa inhibitors
IN Pinto, Donald; Quan, Mimi; Orwat, Michael; Li, Yun-Long; Han, Wei; Qiao, Jennifer; Lam, Patrick; Koch, Stephanie
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 441 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003026652	A1	20030403	WO 2002-US29491	20020917

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2001-324165PP 20010921

OS MARPAT 138:287666
IT **503613-25-0P**, 2-[(4-Chlorobenzoyl)amino]-N-[4-(2-oxo-1-

piperidinyl)phenyl]nicotinamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compd.; prepn. of heteroaryllactams as Factor Xa inhibitors)
RN 503613-25-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(4-chlorobenzoyl)amino]-N-[4-(2-oxo-1-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)



AB P4PMM4 [M = 3-10 membered (substituted) (unsatd.) carbocyclyl, 4-10 membered heeterocyclyl; P = null, 5-7 membered (substituted) (unsatd.) carbocyclyl, heterocyclyl fused to ring M; 1 of P4, M4 = ZAB, the other = G1G; G = (benzo-, pyrido-, pyrimido-, pyrazino-, or pyridazino-fused) (substituted) (unsatd.) 5-6 membered (hetero)cyclyl; G1 = null, (CR3R3a)1-5, etc.; R3, R3a = H, Me, Et, Pr, Ph, PhCH2, etc.; Z = bond, (CR3R3e)1-4, etc.; R3e = H, SO2NHR3, SO2N(R3)2, COR3, (substituted) alkyl, alkenyl, alkynyl, etc.; A = (substituted) 3-10 membered carbocyclyl, 5-12 membered heterocyclyl; Z = XNQ; X = null, CO, SO, SO2, etc.; NQ = 4-8 membered mono- or bicyclic (substituted) (unsatd.) ring contg. a CO or SO2 group adjacent to the N atom; with provisos], were prepd. Thus, 6-(4-iodophenyl)-3-methoxy-1-(4-methoxyphenyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one (prepn. given), .delta.-valerolactam, K2CO3, and CuI were refluxed in Me2SO to give 15% 3-methoxy-1-(4-methoxyphenyl)-6-[4-(2-oxo-1-piperidinyl)phenyl]-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one. Several title compds. inhibited Factor Xa with IC50.ltoreq. 10 .mu.M.
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 20 CAPLUS COPYRIGHT 2003 ACS
AN 2003:22869 CAPLUS
DN 138:89806
TI Preparation of arylpyrazoles as soluble epoxide hydrolase inhibitors for treatment of cardiovascular disease.
IN Ingraham, Richard H.; Proudfoot, John R.
PA Boehringer Ingelheim Pharmaceuticals Inc., USA
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1